Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…
Certara2026 年 5 月 7 日
DIDB® Concomitant Meds Navigator
Explore the Concomitant Meds Navigator withing DIDB - An evidence-based tool within DIDB that helps…
Certara2026 年 4 月 27 日
Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations
Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…
Certara2026 年 3 月 24 日
什么是 Simcyp Discovery 及其如何支持药物发现？
Learn how Simcyp helps in drug discovery, supporting compound selection, first-in-human PK prediction, early DDI…
Certara2026 年 3 月 3 日
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
Certara2025 年 9 月 22 日
Drug Interaction Database (DIDB ®)
Optimize DDI knowledge throughout drug development
Certara2025 年 9 月 19 日
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – 2025 年 9 月 17 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…
Certara2025 年 9 月 17 日
